Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program |Shionogi & Co., Ltd.

2023-04-20 14:03:59 By : Ms. Tyvan Lam

1. Committee regarding the coronavirus disease pandemic. World Health Organization Website. Accessed January 31, 2023. Available at: https://www.who.int/news/item/30-01-2023-statement-on-the-fourteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.

2. Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor. ClinicalTrials.gov Website. Accessed February 15, 2023. Available at https://clinicaltrials.gov/ct2/show/NCT05605093?term=S-217622&draw=2&rank=4. Preservatives And Antioxidants

Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program |Shionogi & Co., Ltd.
Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program |Shionogi & Co., Ltd.

Tartaric Acid 3. NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 press release page. National Institutes of Health Website. Accessed February 15, 2023. Available at https://www.nih.gov/news-events/news-releases/nih-trial-evaluate-shionogi-antiviral-adults-hospitalized-covid-19.